Tonix - Sachs Conf - 1-12-25 vFinal5.pdf

《Tonix - Sachs Conf - 1-12-25 vFinal5.pdf》由会员分享，可在线阅读，更多相关《Tonix - Sachs Conf - 1-12-25 vFinal5.pdf（42页珍藏版）》请在三个皮匠报告上搜索。

1、 2025 Tonix Pharmaceuticals Holding Corp.Corporate PresentationSachs ConferenceJanuary 12,2025NASDAQ:TNXPPO6034,January 12,2025(Doc 1550)2 2025 Tonix Pharmaceuticals Holding Corp.Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans,expectati

2、ons and objectives for future operations or results are“forward-looking statements”as defined by the Private Securities Litigation Reform Act of 1995.These statements may be identified by the use of forward-looking words such as“anticipate,”“believe,”“forecast,”“estimate”and“intend,”among others.The

3、se forward-looking statements are based on Tonixs current expectations and actual results could differ materially.There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.These factors include,but are not limited to,the

4、 risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;risks related to the failure to successfully market any of our products;risks related to the timing and progress of clinical development of our product candidates;our need for additional financing;

5、uncertainties of patent protection and litigation;uncertainties of government or third party payor reimbursement;limited research and development efforts and dependence upon third parties;and substantial competition.As with any pharmaceutical under development,there are significant risks in the deve

6、lopment,regulatory approval and commercialization of new products.The forward-looking statements in this presentation are made as of the date of this presentation,even if subsequently made available by Tonix on its website or otherwise.Tonix does not undertake an obligation to update or revise any f